Macrogen said Monday that it has signed a memorandum of understanding with Microba, an Australian-based company, to collaborate on microbiome research.
|Macrogen CEO Yang Kap-seok and Microba CEO Blake Wills shake hands while holding up their agreement at Macrogen headquarters in Gasan-dong, southwestern Seoul, last Thursday.|
Under the accord, the two companies will establish a close cooperation system for the advancement of the microbiome market both at home and abroad by exchanging analysis technology, conducting joint research for advanced analytical technique, and developing microbiome services.
In particular, the two companies will develop a microbiome service which uses a shotgun sequencing method that analyzes the whole genome for all microorganisms. The service is an upgrade from the conventional 16S rRNA analysis, which only arranges specific parts of the bacteria.
“We are delighted to cooperate with Macrogen, which has world-class gene analysis scale and accumulated experience of many years,” Microba CEO Blake Wills said. “We intend to collaborate closely with Macrogen to enhance the microbiome analytical technology, as well as jointly developing a direct consumer platform, and services for research and clinical applications.”
Macrogen CEO Yang Kap-seok also said, “Microba has accumulated overwhelming technological advantage in the market by accumulating various research achievements in the field of the microbiome.”
Through this business agreement, Microgen will develop a reliable service that maximizes the synergy between the two companies and plan to launch services sequentially to the global markets such as the U.S., Europe, Japan and Singapore, Yang added.
<© Korea Biomedical Review, All rights reserved.>